Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders
- PMID: 25042691
- PMCID: PMC4177960
- DOI: 10.1016/j.ymgme.2014.06.005
Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders
Abstract
Sodium phenylbutyrate (NaPBA) is a commonly used medication for the treatment of patients with urea cycle disorders (UCDs). Previous reports involving small numbers of patients with UCDs have shown that NaPBA treatment can result in lower plasma levels of the branched-chain amino acids (BCAA) but this has not been studied systematically. From a large cohort of patients (n=553) with UCDs enrolled in the Longitudinal Study of Urea Cycle Disorders, a collaborative multicenter study of the Urea Cycle Disorders Consortium, we evaluated whether treatment with NaPBA leads to a decrease in plasma BCAA levels. Our analysis shows that NaPBA use independently affects the plasma BCAA levels even after accounting for multiple confounding covariates. Moreover, NaPBA use increases the risk for BCAA deficiency. This effect of NaPBA seems specific to plasma BCAA levels, as levels of other essential amino acids are not altered by its use. Our study, in an unselected population of UCD subjects, is the largest to analyze the effects of NaPBA on BCAA metabolism and potentially has significant clinical implications. Our results indicate that plasma BCAA levels should to be monitored in patients treated with NaPBA since patients taking the medication are at increased risk for BCAA deficiency. On a broader scale, these findings could open avenues to explore NaPBA as a therapy in maple syrup urine disease and other common complex disorders with dysregulation of BCAA metabolism.
Keywords: Branched-chain amino acids; Sodium phenylbutyrate; Urea cycle disorder.
Copyright © 2014 Elsevier Inc. All rights reserved.
Figures

References
-
- Burlina AB, Ogier H, Korall H, Trefz FK. Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab. 2001;72:351–355. - PubMed
-
- Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res. 1991;29:147–150. - PubMed
-
- Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science. 1980;207:659–661. - PubMed
-
- Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138:S46–S54. discussion S54–45. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 RR000188/RR/NCRR NIH HHS/United States
- R01 DK092921/DK/NIDDK NIH HHS/United States
- R01 DK102641/DK/NIDDK NIH HHS/United States
- HD024064/HD/NICHD NIH HHS/United States
- 2013095/DDCF/Doris Duke Charitable Foundation/United States
- P30 HD024064/HD/NICHD NIH HHS/United States
- RR00188/RR/NCRR NIH HHS/United States
- DK92921/DK/NIDDK NIH HHS/United States
- U54HD061221/HD/NICHD NIH HHS/United States
- T32 GM007526/GM/NIGMS NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- U54 HD083092/HD/NICHD NIH HHS/United States
- U54 HD061221/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical